AML are characterized by blocked differentiation and an excessive accumulation of hematopoietic stem and/or progenitor cells. This is due to a variety of genetic errors that include aberrant expression of fusion oncoproteins, mutant myeloid transcriptor factors, mutant cytokine receptors, truncated granulocyte colony-stimulating factor receptor or unknown errors. The PharmaFlow platform allows the screening of drug candidates in AML patients, evaluating the potential differentiation capacity of blast cells adding a panel of terminal granulocytic or monocytic markers. Additional staining for cell viability (ie, Annexin-V) or normal populations (ie, Lymphocytes) contribute for the simultaneous analysis of both blast-maturation and toxicity, selecting those candidates with better effect and non-toxic profile.